결장-직장암 환자에서 혈장 TGF-β1 농도의 증가
Increase of Plasma TGF-β1 Level in Colorectal Cancer Patients
임창기, 최인영, 신훈, 류민희, 손승국, 진승원,
소속 상세정보
임창기 ( Lim Chang-Ki )
한미약품 중앙연구소
최인영 ( Choi In-Young )
한미약품 중앙연구소
신훈 ( Shin Hoon )
한미약품 중앙연구소
류민희 ( Ryu Min-Hee )
서울대학교 의과대학 혈액종양내과
손승국 ( Son Seung-Kook )
연세대학교 의과대학 세브란스병원 일반외과
진승원 ( Jin Seung-Won )
한미약품 중앙연구소
KMID : 0356720010170030135
Abstract
Purpose: Many kinds of malignant tissues, including colorectal cancer were reported to overexpress transforming growth factor-β1 (TGF-β1) gene. However, little work has been done on the circulating TGF-β1 and the association of TGF-β1 with progression in patients with malignant tumors. In this study, we measured the plasma level of TGF-β1 in colorectal cancer patients.
Methods: Enzyme-linked immunosorbent assay (ELISA) was used to measure plasma TGF-β1 level in 52 colorectal cancer patients and 290 normal controls. And carcinoembryonic antigen (CEA) as a tumor marker was compared with TGF-β1 in the aspects of sensitivity and specificity.
Results: The mean plasma TGF-β1 levels were 1.2 19 0.834 (0.272∼5.772) ng/mL in normal control and 8.207 2.428 (1.392∼39.241) ng/mL in colorectal cancer. In comparison with CEA, TGF-β1 is more potent in cancer diagnostic sensitivity.
Conclusion: The results of this study suggest that the plasma TGF-β1 level can be a useful tumor marker in colorectal cancer patients.
키워드
암태아성 항원; 결장-직장암;효소 면역 측정법;형질전환 성장 인자;종양 표지자
CEA;Colorectal cancer;ELISA;TGF-β1;Tumor marker
원문 및 링크아웃 정보
등재저널 정보